title: [Drug treatment of osteoporosis].
authors.affiliation: Medizinische Laboratorien Dr. F. Käppeli AG, Zürich.
authors.forename: W J
authors.initials: WJ
authors.lastname: Fassbender
authors.affiliation: Hirslanden.
authors.forename: B
authors.initials: B
authors.lastname: Willmann
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002136:Calcium, Dietary / Q000008:administration & dosage; D002423:Cause of Death; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005858:Germany; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D058866:Osteoporotic Fractures / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D011157:Population Dynamics; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use; D014807:Vitamin D / Q000008:administration & dosage
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001713:Biphenyl Compounds; D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D014807:Vitamin D; D000069448:Denosumab; C527128:odanacatib